Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.36 USD
Change Today +0.0901 / 0.88%
Volume 16.7K
IRIX On Other Exchanges
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

iridex corp (IRIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $11.28
52 Week Low
10/22/14 - $6.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IRIDEX CORP (IRIX)

Related News

No related news articles were found.

iridex corp (IRIX) Related Businessweek News

No Related Businessweek News Found

iridex corp (IRIX) Details

IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases worldwide. Its ophthalmology products consist of laser consoles, such as visible (yellow) photocoagulator console, infrared photocoagulator consoles, micropulse enabled consoles, and multi-wavelength laser system configurations. The company also provides ophthalmic delivery devices and other products, such as TxCell scanning laser delivery systems; TruFocus laser indirect ophthalmoscopes; slit lamp adapters; and operating microscope adapters. In addition, it offers EndoProbe, a fiber optic delivery device used for endophotocoagulation, a retinal treatment procedure; G-Probe, a sterile consumable multi-use product used in procedures to treat medically and surgically uncontrolled glaucoma; and DioPexy Probe, a hand-held instrument used in procedures to treat retinal tears. Further, the company provides GreenTip Soft Tip Cannula, a sterile disposable product, which allows surgeons to visualize and access the proximity of the retina while performing a fluid air exchange during a vitrectomy procedure; and MoistAir in-line air humidifier that provides humidified air to the eye during fluid air exchange. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It sells and markets its products through a direct sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

iridex corp (IRIX) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $200.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $284.7K
Compensation as of Fiscal Year 2013.

iridex corp (IRIX) Key Developments

IRIDEX Corporation Announces First Commercial Sales of New Cyclo G6™ Glaucoma Laser Systems

IRIDEX Corporation announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable. Glaucoma is an eye disease that causes damage to the optic nerve, which carries images from the retina to the brain. In glaucoma, heightened eye pressure can lead to progressive damage of the delicate nerve fibers of the optic nerve. The Cyclo G6 offers repeatable and minimally invasive approaches to slowing the progress of the disease.

IRIDEX Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended January 3, 2015; Provides Earnings Guidance for the First Quarter of 2015

IRIDEX Corporation reported unaudited consolidated earnings results for the fourth quarter and year ended January 3, 2015. For the quarter, the company reported total revenues of $11,778,000, income from operations of $984,000, income from operations before (benefit from) provision for income taxes of $29,000 and net income of $8,764,000 or $0.86 per diluted share. For the year, the company reported total revenues of $42,814,000, income from operations of $2,587,000, income from operations before (benefit from) provision for income taxes of $1,332,000 and net income of $10,038,000 or $0.97 per diluted share. For the 2015 first quarter, the company anticipates revenue of $10.8 million to $11.2 million, gross margin is anticipated to come in between 49% and 51%.

IRIDEX Corporation to Report Q4, 2014 Results on Mar 05, 2015

IRIDEX Corporation announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRIX:US $10.36 USD +0.0901

IRIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cutera Inc $13.30 USD +0.23
Ellex Medical Lasers Ltd A$0.33 AUD +0.02
Lutronic Corp 34,000 KRW +100.00
STAAR Surgical Co $7.25 USD -0.01
Synergetics USA Inc $5.30 USD -0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation IRIX Industry Range
Price/Earnings 10.6x
Price/Sales 2.4x
Price/Book 3.0x
Price/Cash Flow 10.1x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIDEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at